An SGLT2 inhibitor (IC50 = 3.1 nM for the human transporter); reduces non-fasting blood glucose levels, as well as aortic superoxide levels and cardiac interstitial fibrosis, in db/db mice when administered in the diet at 0.03%; decreases the severity of glomerulosclerosis, as well as reduces the escape latency in the Morris water maze, in the same model